KIR3DL3 and lung carcinoma: Using immunodeficient mice challenged with the HHLA2+ human lung cancer cell HCC827 and injected with KIR3DL3+-expanded human NK cells, Wei et al. demonstrated that KIR3DL3 blockade enhances NK cell-mediated protection in vivo.